West Pharmaceutical Services (WST) Operating Leases (2019 - 2026)

West Pharmaceutical Services has disclosed Operating Leases across 8 years of filings, most recently posting $109.2 million for Q2 2026.

• In Q2 2026, Operating Leases rose 8.44% year-over-year to $109.2 million; the TTM figure through Jun 2026 stood at $109.2 million (up 8.44% YoY), while the FY2025 annual figure was $95.6 million, up 16.87% from the prior year.
• Operating Leases came in at $109.2 million for Q2 2026 at West Pharmaceutical Services, down from $113.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $113.4 million in Q1 2026 to a low of $78.7 million in Q1 2022.
• Average Operating Leases over 5 years is $96.7 million, with a median of $99.9 million recorded in 2023.
• Year-over-year, Operating Leases soared 47.62% in 2022 and dropped 9.14% in 2023.
• Over 5 years, Operating Leases stood at $93.0 million in 2022, then slipped by 9.14% to $84.5 million in 2023, then decreased by 3.2% to $81.8 million in 2024, then rose by 16.87% to $95.6 million in 2025, then rose by 14.23% to $109.2 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $109.2 million in Q2 2026, $113.4 million in Q1 2026, and $95.6 million in Q4 2025.